Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus subtilis + bacillus clausii + bacillus coagulans
- Development stage
- Unknown
- Lead developer
- Advanced Enzyme Technologies
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A combination probiotic formulation containing three spore-forming bacterial species: **Bacillus subtilis**, **Bacillus clausii**, and **Bacillus coagulans**. These Gram-positive, spore-forming bacteria are used as oral probiotics to support gastrointestinal health, promote microbiome diversity, and provide immunomodulatory benefits. The combination has demonstrated beneficial effects in relieving gastrointestinal complaints, improving stool consistency, reducing abdominal discomfort, and supporting the immune system by modulating inflammatory markers and immune cell function in clinical and preclinical studies. Used as a dietary supplement for gut health, prevention of dysbiosis, and as an adjunct in conditions like acute allergic rhinitis and episodes of diarrhea. Mechanistic actions include colonization resistance, competitive exclusion of pathogens, production of lactic acid (by B. coagulans), stimulation of growth of beneficial intestinal flora, and moderation of immune responses[1][2][3][4][7].
- Brand names
- Ortho Spore IG
Beyond the preview
Go deeper on bacillus subtilis + bacillus clausii + bacillus coagulans.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus subtilis + bacillus clausii + bacillus coagulans.